Testosterone Level Reduction Increases the 10-Year Risk of Cardiovascular Diseases: A Retrospective Cohort Study in a Taiwanese Young Male Population

• Published in: Frontiers in cardiovascular medicine Vol. 9; p. 869251
• Main Authors: Yang, Han-Hsuan, Tu, Shih-Kai, Chen, Hsin-Hung, Hung, Chia-Lien, Kuo, Chia-Wen, Tsan, Yu-Tse, Chu, Wei-Min, Lee, Meng-Chih, Liao, Chun-Cheng
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 14.04.2022
• Subjects: ASCVD Risk Estimator; cardiovascular disease; cardiovascular disease risk; Cardiovascular Medicine; cohort study; Framingham Risk Score; testosterone; ASCVD Risk Estimator; cardiovascular disease; cohort study; testosterone; cardiovascular disease risk; Framingham Risk Score
• ISSN: 2297-055X; 2297-055X
• DOI: 10.3389/fcvm.2022.869251

Low testosterone levels are associated with increased risk of cardiovascular disease; however, most previous studies assessed the relationship of testosterone levels with a history of cardiovascular (CV) events rather than with CV risk prediction scores consequently neglecting the effect of testosterone on CV risk in healthy young individuals. The aim of this study was to investigate the relationship between testosterone levels and predict the 10-year risk of cardiovascular disease. This retrospective cohort study was conducted through a large medical health examination system in four metropolises in Taiwan. Two risk scores were used to predict the 10-year cardiovascular risk of participants: the Framingham Risk Score (FRS) (2008) and the Atherosclerotic Cardiovascular Disease (ASCVD) Risk Estimator (2013). Multivariate-adjusted logistic regression was used to calculate odds ratios (ORs) for the correlation of testosterone level reduction with the increase in predicted CV risk. We used the MJ Health Research Foundation database to collect reports of 125,414 individuals who underwent medical checkups between 2007 and 2016. The final sample size included 1,253 male participants. A reduction in testosterone level between two subsequent medical checkups was associated with higher CV risk estimated by the FRS and ASCVD Risk Estimator in young participants aged 30-49 years (OR = 0.804, 95% CI: 0.711-0.909, p < 0.01 and OR = 0.841, 95% CI: 0.742-0.953, p < 0.01, respectively). Reduction in total testosterone levels increases CV risk in men aged 30 to 49 years, while the CV risk is not influenced by low testosterone levels at baseline.